Adrafinil / modafinil analog stimulants
Cognitive · Wakefulness-promoting research chemical
Tier D+
Bottom line
Read Off Label grades Adrafinil / modafinil analog stimulants as D+ (3.9/10) based on weak evidence, med benefit magnitude, and a unknown-med-risk safety profile.
WADA coverage: adrafinil, fladrafinil, flmodafinil and hydrafinil/fluorenol.
Studied, labeled, or reported-use context: No approved enhancement dose for analogs — Not FDA-approved as supplements; legal status varies; WADA S6 prohibited in competition; not individualized guidance.
What the evidence says
WADA coverage: adrafinil, fladrafinil, flmodafinil and hydrafinil/fluorenol. Modafinil and armodafinil keep their own Rx rows. Additional WADA alias coverage: Fladrafinil (2-[Bis(4-fluorophenyl)methylsulfinyl]-N-hydroxyacetamide) and Flmodafinil (2-[Bis(4-fluorophenyl)methylsulfinyl]acetamide). Fonturacetam [4-phenylpiracetam (carphedon)] is covered by the dedicated Phenylpiracetam row.
Mechanism
Adrafinil is a prodrug-like predecessor to modafinil; fladrafinil, flmodafinil and hydrafinil are gray-market analogs pursued for wakefulness and focus.
Studied, labeled, or reported dose & route
No approved enhancement dose for analogs
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Adrafinil / modafinil analog stimulants's effects?
- Read Off Label rates the evidence for Adrafinil / modafinil analog stimulants as Weak and the benefit magnitude as med, producing an overall grade of D+ (3.9/10). WADA coverage: adrafinil, fladrafinil, flmodafinil and hydrafinil/fluorenol.
- What safety findings are reported for Adrafinil / modafinil analog stimulants?
- Adrafinil / modafinil analog stimulants has a unknown-med risk profile in the database. Unknown-Med (liver-enzyme concerns for adrafinil, insomnia/anxiety/BP effects, product-quality risk) Legal status: Not FDA-approved as supplements; legal status varies; WADA S6 prohibited in competition.
- What doses or routes are reported for Adrafinil / modafinil analog stimulants?
- No approved enhancement dose for analogs This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Adrafinil / modafinil analog stimulants work?
- Adrafinil is a prodrug-like predecessor to modafinil; fladrafinil, flmodafinil and hydrafinil are gray-market analogs pursued for wakefulness and focus.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.